Aurora Spine Corporation

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, SMMNY has a market cap of 92B. Regarding current trading prices, ASAPF is priced at $0.18, while SMMNY trades at $20.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas SMMNY's P/E ratio is 18.58. In terms of profitability, ASAPF's ROE is -0.32%, compared to SMMNY's ROE of +0.11%. Regarding short-term risk, ASAPF is more volatile compared to SMMNY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check SMMNY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, SEMHF has a market cap of 47B. Regarding current trading prices, ASAPF is priced at $0.18, while SEMHF trades at $42.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas SEMHF's P/E ratio is 19.21. In terms of profitability, ASAPF's ROE is -0.32%, compared to SEMHF's ROE of +0.11%. Regarding short-term risk, ASAPF is more volatile compared to SEMHF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check SEMHF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, RYLPF has a market cap of 25.2B. Regarding current trading prices, ASAPF is priced at $0.18, while RYLPF trades at $26.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas RYLPF's P/E ratio is 24.50. In terms of profitability, ASAPF's ROE is -0.32%, compared to RYLPF's ROE of +0.08%. Regarding short-term risk, ASAPF is more volatile compared to RYLPF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check RYLPF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, SNNUF has a market cap of 13.6B. Regarding current trading prices, ASAPF is priced at $0.18, while SNNUF trades at $16.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas SNNUF's P/E ratio is 22.29. In terms of profitability, ASAPF's ROE is -0.32%, compared to SNNUF's ROE of +0.12%. Regarding short-term risk, ASAPF is more volatile compared to SNNUF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check SNNUF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, SONVY has a market cap of 12.9B. Regarding current trading prices, ASAPF is priced at $0.18, while SONVY trades at $43.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas SONVY's P/E ratio is 19.53. In terms of profitability, ASAPF's ROE is -0.32%, compared to SONVY's ROE of +0.20%. Regarding short-term risk, ASAPF is more volatile compared to SONVY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check SONVY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, SONVF has a market cap of 12.8B. Regarding current trading prices, ASAPF is priced at $0.18, while SONVF trades at $214.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas SONVF's P/E ratio is 19.43. In terms of profitability, ASAPF's ROE is -0.32%, compared to SONVF's ROE of +0.20%. Regarding short-term risk, ASAPF is more volatile compared to SONVF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check SONVF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, CHEOF has a market cap of 7.8B. Regarding current trading prices, ASAPF is priced at $0.18, while CHEOF trades at $119.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas CHEOF's P/E ratio is 28.96. In terms of profitability, ASAPF's ROE is -0.32%, compared to CHEOF's ROE of +0.18%. Regarding short-term risk, ASAPF is more volatile compared to CHEOF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check CHEOF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, CHEOY has a market cap of 7.6B. Regarding current trading prices, ASAPF is priced at $0.18, while CHEOY trades at $58.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas CHEOY's P/E ratio is 31.49. In terms of profitability, ASAPF's ROE is -0.32%, compared to CHEOY's ROE of +0.18%. Regarding short-term risk, ASAPF is more volatile compared to CHEOY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check CHEOY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, WILLF has a market cap of 6B. Regarding current trading prices, ASAPF is priced at $0.18, while WILLF trades at $28.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas WILLF's P/E ratio is 16.26. In terms of profitability, ASAPF's ROE is -0.32%, compared to WILLF's ROE of +0.16%. Regarding short-term risk, ASAPF is more volatile compared to WILLF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check WILLF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, WILYY has a market cap of 5.9B. Regarding current trading prices, ASAPF is priced at $0.18, while WILYY trades at $13.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas WILYY's P/E ratio is 15.46. In terms of profitability, ASAPF's ROE is -0.32%, compared to WILYY's ROE of +0.16%. Regarding short-term risk, ASAPF is more volatile compared to WILYY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check WILYY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, GNGBF has a market cap of 5.9B. Regarding current trading prices, ASAPF is priced at $0.18, while GNGBF trades at $23.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas GNGBF's P/E ratio is 25.25. In terms of profitability, ASAPF's ROE is -0.32%, compared to GNGBF's ROE of +0.08%. Regarding short-term risk, ASAPF is more volatile compared to GNGBF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check GNGBF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, GNGBY has a market cap of 5.3B. Regarding current trading prices, ASAPF is priced at $0.18, while GNGBY trades at $19.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas GNGBY's P/E ratio is 21.74. In terms of profitability, ASAPF's ROE is -0.32%, compared to GNGBY's ROE of +0.08%. Regarding short-term risk, ASAPF is more volatile compared to GNGBY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check GNGBY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, AMBFF has a market cap of 3.7B. Regarding current trading prices, ASAPF is priced at $0.18, while AMBFF trades at $13.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas AMBFF's P/E ratio is 42.66. In terms of profitability, ASAPF's ROE is -0.32%, compared to AMBFF's ROE of +0.09%. Regarding short-term risk, ASAPF is more volatile compared to AMBFF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check AMBFF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, NHNKY has a market cap of 2.9B. Regarding current trading prices, ASAPF is priced at $0.18, while NHNKY trades at $9.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas NHNKY's P/E ratio is 13.04. In terms of profitability, ASAPF's ROE is -0.32%, compared to NHNKY's ROE of +0.07%. Regarding short-term risk, ASAPF is more volatile compared to NHNKY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check NHNKY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, MCRPF has a market cap of 2.9B. Regarding current trading prices, ASAPF is priced at $0.18, while MCRPF trades at $1.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas MCRPF's P/E ratio is -17.44. In terms of profitability, ASAPF's ROE is -0.32%, compared to MCRPF's ROE of -0.27%. Regarding short-term risk, ASAPF is more volatile compared to MCRPF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check MCRPF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, AMBBY has a market cap of 2.7B. Regarding current trading prices, ASAPF is priced at $0.18, while AMBBY trades at $10.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas AMBBY's P/E ratio is 32.24. In terms of profitability, ASAPF's ROE is -0.32%, compared to AMBBY's ROE of +0.09%. Regarding short-term risk, ASAPF is more volatile compared to AMBBY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check AMBBY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, NHNKF has a market cap of 2.4B. Regarding current trading prices, ASAPF is priced at $0.18, while NHNKF trades at $15.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas NHNKF's P/E ratio is 41.86. In terms of profitability, ASAPF's ROE is -0.32%, compared to NHNKF's ROE of +0.07%. Regarding short-term risk, ASAPF is more volatile compared to NHNKF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check NHNKF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, GNNDY has a market cap of 2.1B. Regarding current trading prices, ASAPF is priced at $0.18, while GNNDY trades at $43.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas GNNDY's P/E ratio is 20.83. In terms of profitability, ASAPF's ROE is -0.32%, compared to GNNDY's ROE of +0.06%. Regarding short-term risk, ASAPF is more volatile compared to GNNDY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check GNNDY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, DRWKF has a market cap of 2.1B. Regarding current trading prices, ASAPF is priced at $0.18, while DRWKF trades at $109.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas DRWKF's P/E ratio is 12.70. In terms of profitability, ASAPF's ROE is -0.32%, compared to DRWKF's ROE of +0.09%. Regarding short-term risk, ASAPF is more volatile compared to DRWKF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check DRWKF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, GGNDF has a market cap of 2B. Regarding current trading prices, ASAPF is priced at $0.18, while GGNDF trades at $13.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas GGNDF's P/E ratio is 19.64. In terms of profitability, ASAPF's ROE is -0.32%, compared to GGNDF's ROE of +0.06%. Regarding short-term risk, ASAPF is more volatile compared to GGNDF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check GGNDF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, FDMDF has a market cap of 1.8B. Regarding current trading prices, ASAPF is priced at $0.18, while FDMDF trades at $3.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas FDMDF's P/E ratio is -11.29. In terms of profitability, ASAPF's ROE is -0.32%, compared to FDMDF's ROE of -9.21%. Regarding short-term risk, ASAPF is more volatile compared to FDMDF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check FDMDF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, OSSFF has a market cap of 1.8B. Regarding current trading prices, ASAPF is priced at $0.18, while OSSFF trades at $4.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas OSSFF's P/E ratio is 20.75. In terms of profitability, ASAPF's ROE is -0.32%, compared to OSSFF's ROE of +0.10%. Regarding short-term risk, ASAPF is more volatile compared to OSSFF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check OSSFF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, DWRKF has a market cap of 1.8B. Regarding current trading prices, ASAPF is priced at $0.18, while DWRKF trades at $543.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas DWRKF's P/E ratio is 75.94. In terms of profitability, ASAPF's ROE is -0.32%, compared to DWRKF's ROE of N/A. Regarding short-term risk, ASAPF is more volatile compared to DWRKF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check DWRKF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, STSEY has a market cap of 1.7B. Regarding current trading prices, ASAPF is priced at $0.18, while STSEY trades at $5.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas STSEY's P/E ratio is 19.00. In terms of profitability, ASAPF's ROE is -0.32%, compared to STSEY's ROE of +0.07%. Regarding short-term risk, ASAPF is more volatile compared to STSEY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check STSEY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, MEDGF has a market cap of 1.7B. Regarding current trading prices, ASAPF is priced at $0.18, while MEDGF trades at $83.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas MEDGF's P/E ratio is 33.30. In terms of profitability, ASAPF's ROE is -0.32%, compared to MEDGF's ROE of +0.22%. Regarding short-term risk, ASAPF is more volatile compared to MEDGF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check MEDGF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, OSSUY has a market cap of 1.6B. Regarding current trading prices, ASAPF is priced at $0.18, while OSSUY trades at $3.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas OSSUY's P/E ratio is 19.08. In terms of profitability, ASAPF's ROE is -0.32%, compared to OSSUY's ROE of +0.10%. Regarding short-term risk, ASAPF is more volatile compared to OSSUY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check OSSUY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, VTRLY has a market cap of 1.5B. Regarding current trading prices, ASAPF is priced at $0.18, while VTRLY trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas VTRLY's P/E ratio is -2.77. In terms of profitability, ASAPF's ROE is -0.32%, compared to VTRLY's ROE of -0.42%. Regarding short-term risk, ASAPF is more volatile compared to VTRLY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check VTRLY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, DGWPF has a market cap of 1.5B. Regarding current trading prices, ASAPF is priced at $0.18, while DGWPF trades at $76.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas DGWPF's P/E ratio is 8.89. In terms of profitability, ASAPF's ROE is -0.32%, compared to DGWPF's ROE of +0.09%. Regarding short-term risk, ASAPF is more volatile compared to DGWPF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check DGWPF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, MDRSF has a market cap of 1.4B. Regarding current trading prices, ASAPF is priced at $0.18, while MDRSF trades at $115.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas MDRSF's P/E ratio is 135.29. In terms of profitability, ASAPF's ROE is -0.32%, compared to MDRSF's ROE of +0.03%. Regarding short-term risk, ASAPF is more volatile compared to MDRSF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check MDRSF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, ELEAF has a market cap of 1.3B. Regarding current trading prices, ASAPF is priced at $0.18, while ELEAF trades at $16.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas ELEAF's P/E ratio is 23.06. In terms of profitability, ASAPF's ROE is -0.32%, compared to ELEAF's ROE of +0.16%. Regarding short-term risk, ASAPF is more volatile compared to ELEAF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check ELEAF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, LFTSF has a market cap of 1B. Regarding current trading prices, ASAPF is priced at $0.18, while LFTSF trades at $0.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas LFTSF's P/E ratio is 23.35. In terms of profitability, ASAPF's ROE is -0.32%, compared to LFTSF's ROE of +0.02%. Regarding short-term risk, ASAPF is more volatile compared to LFTSF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check LFTSF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, XVIPF has a market cap of 603.2M. Regarding current trading prices, ASAPF is priced at $0.18, while XVIPF trades at $19.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas XVIPF's P/E ratio is 212.78. In terms of profitability, ASAPF's ROE is -0.32%, compared to XVIPF's ROE of +0.01%. Regarding short-term risk, ASAPF is more volatile compared to XVIPF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check XVIPF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, AVMR has a market cap of 494.2M. Regarding current trading prices, ASAPF is priced at $0.18, while AVMR trades at $9.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas AVMR's P/E ratio is -18.34. In terms of profitability, ASAPF's ROE is -0.32%, compared to AVMR's ROE of -0.30%. Regarding short-term risk, ASAPF is more volatile compared to AVMR. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check AVMR's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, DMTRF has a market cap of 476M. Regarding current trading prices, ASAPF is priced at $0.18, while DMTRF trades at $3.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas DMTRF's P/E ratio is -198.00. In terms of profitability, ASAPF's ROE is -0.32%, compared to DMTRF's ROE of +0.36%. Regarding short-term risk, ASAPF is more volatile compared to DMTRF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check DMTRF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, BRSYF has a market cap of 475.2M. Regarding current trading prices, ASAPF is priced at $0.18, while BRSYF trades at $11.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas BRSYF's P/E ratio is 74.19. In terms of profitability, ASAPF's ROE is -0.32%, compared to BRSYF's ROE of +0.12%. Regarding short-term risk, ASAPF is more volatile compared to BRSYF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check BRSYF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, IOBCF has a market cap of 439.6M. Regarding current trading prices, ASAPF is priced at $0.18, while IOBCF trades at $15.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas IOBCF's P/E ratio is 22.39. In terms of profitability, ASAPF's ROE is -0.32%, compared to IOBCF's ROE of +0.15%. Regarding short-term risk, ASAPF is more volatile compared to IOBCF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check IOBCF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, CALZF has a market cap of 414.5M. Regarding current trading prices, ASAPF is priced at $0.18, while CALZF trades at $0.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas CALZF's P/E ratio is 60.00. In terms of profitability, ASAPF's ROE is -0.32%, compared to CALZF's ROE of +0.12%. Regarding short-term risk, ASAPF is more volatile compared to CALZF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check CALZF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, CLVSF has a market cap of 384.8M. Regarding current trading prices, ASAPF is priced at $0.18, while CLVSF trades at $16.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas CLVSF's P/E ratio is 23.38. In terms of profitability, ASAPF's ROE is -0.32%, compared to CLVSF's ROE of +0.18%. Regarding short-term risk, ASAPF is more volatile compared to CLVSF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check CLVSF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, CSSPF has a market cap of 384.5M. Regarding current trading prices, ASAPF is priced at $0.18, while CSSPF trades at $0.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas CSSPF's P/E ratio is 92.00. In terms of profitability, ASAPF's ROE is -0.32%, compared to CSSPF's ROE of +0.10%. Regarding short-term risk, ASAPF is more volatile compared to CSSPF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check CSSPF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, HYBT has a market cap of 361.4M. Regarding current trading prices, ASAPF is priced at $0.18, while HYBT trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas HYBT's P/E ratio is N/A. In terms of profitability, ASAPF's ROE is -0.32%, compared to HYBT's ROE of +0.02%. Regarding short-term risk, ASAPF is more volatile compared to HYBT. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check HYBT's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, CYBQY has a market cap of 338.8M. Regarding current trading prices, ASAPF is priced at $0.18, while CYBQY trades at $1.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas CYBQY's P/E ratio is -190.00. In terms of profitability, ASAPF's ROE is -0.32%, compared to CYBQY's ROE of -0.00%. Regarding short-term risk, ASAPF is more volatile compared to CYBQY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check CYBQY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, HTLZF has a market cap of 245.1M. Regarding current trading prices, ASAPF is priced at $0.18, while HTLZF trades at $1.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas HTLZF's P/E ratio is -159.01. In terms of profitability, ASAPF's ROE is -0.32%, compared to HTLZF's ROE of -0.01%. Regarding short-term risk, ASAPF is more volatile compared to HTLZF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check HTLZF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, CYBQF has a market cap of 229.5M. Regarding current trading prices, ASAPF is priced at $0.18, while CYBQF trades at $1.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas CYBQF's P/E ratio is -172.00. In terms of profitability, ASAPF's ROE is -0.32%, compared to CYBQF's ROE of -0.00%. Regarding short-term risk, ASAPF is more volatile compared to CYBQF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check CYBQF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, IMPZY has a market cap of 200.8M. Regarding current trading prices, ASAPF is priced at $0.18, while IMPZY trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas IMPZY's P/E ratio is -1.60. In terms of profitability, ASAPF's ROE is -0.32%, compared to IMPZY's ROE of +13.22%. Regarding short-term risk, ASAPF is more volatile compared to IMPZY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check IMPZY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, VMTHF has a market cap of 184.7M. Regarding current trading prices, ASAPF is priced at $0.18, while VMTHF trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas VMTHF's P/E ratio is -2.01. In terms of profitability, ASAPF's ROE is -0.32%, compared to VMTHF's ROE of -0.30%. Regarding short-term risk, ASAPF is more volatile compared to VMTHF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check VMTHF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, DTXMF has a market cap of 180.6M. Regarding current trading prices, ASAPF is priced at $0.18, while DTXMF trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas DTXMF's P/E ratio is -9.52. In terms of profitability, ASAPF's ROE is -0.32%, compared to DTXMF's ROE of -0.74%. Regarding short-term risk, ASAPF is more volatile compared to DTXMF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check DTXMF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, PXMBF has a market cap of 149.9M. Regarding current trading prices, ASAPF is priced at $0.18, while PXMBF trades at $3.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas PXMBF's P/E ratio is 29.17. In terms of profitability, ASAPF's ROE is -0.32%, compared to PXMBF's ROE of -0.04%. Regarding short-term risk, ASAPF is more volatile compared to PXMBF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check PXMBF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, EKDHF has a market cap of 146.7M. Regarding current trading prices, ASAPF is priced at $0.18, while EKDHF trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas EKDHF's P/E ratio is 33.98. In terms of profitability, ASAPF's ROE is -0.32%, compared to EKDHF's ROE of +0.03%. Regarding short-term risk, ASAPF is more volatile compared to EKDHF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check EKDHF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, CLLKF has a market cap of 140.2M. Regarding current trading prices, ASAPF is priced at $0.18, while CLLKF trades at $2.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas CLLKF's P/E ratio is -0.85. In terms of profitability, ASAPF's ROE is -0.32%, compared to CLLKF's ROE of -0.50%. Regarding short-term risk, ASAPF is more volatile compared to CLLKF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check CLLKF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, EAPIF has a market cap of 120.9M. Regarding current trading prices, ASAPF is priced at $0.18, while EAPIF trades at $1.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas EAPIF's P/E ratio is -0.84. In terms of profitability, ASAPF's ROE is -0.32%, compared to EAPIF's ROE of -0.24%. Regarding short-term risk, ASAPF is more volatile compared to EAPIF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check EAPIF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, AMEUF has a market cap of 120.5M. Regarding current trading prices, ASAPF is priced at $0.18, while AMEUF trades at $5.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas AMEUF's P/E ratio is -1.75. In terms of profitability, ASAPF's ROE is -0.32%, compared to AMEUF's ROE of -1.90%. Regarding short-term risk, ASAPF is less volatile compared to AMEUF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check AMEUF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, SOMNF has a market cap of 111.7M. Regarding current trading prices, ASAPF is priced at $0.18, while SOMNF trades at $0.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas SOMNF's P/E ratio is -51.00. In terms of profitability, ASAPF's ROE is -0.32%, compared to SOMNF's ROE of -0.05%. Regarding short-term risk, ASAPF is more volatile compared to SOMNF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check SOMNF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, BCCOY has a market cap of 103.6M. Regarding current trading prices, ASAPF is priced at $0.18, while BCCOY trades at $0.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas BCCOY's P/E ratio is -0.62. In terms of profitability, ASAPF's ROE is -0.32%, compared to BCCOY's ROE of -0.50%. Regarding short-term risk, ASAPF is more volatile compared to BCCOY. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check BCCOY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, AVHHL has a market cap of 99.4M. Regarding current trading prices, ASAPF is priced at $0.18, while AVHHL trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas AVHHL's P/E ratio is -2.22. In terms of profitability, ASAPF's ROE is -0.32%, compared to AVHHL's ROE of +4.77%. Regarding short-term risk, ASAPF is more volatile compared to AVHHL. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check AVHHL's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, JMDMF has a market cap of 94.1M. Regarding current trading prices, ASAPF is priced at $0.18, while JMDMF trades at $3.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas JMDMF's P/E ratio is -13.68. In terms of profitability, ASAPF's ROE is -0.32%, compared to JMDMF's ROE of N/A. Regarding short-term risk, ASAPF is more volatile compared to JMDMF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check JMDMF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, RSHUF has a market cap of 91.5M. Regarding current trading prices, ASAPF is priced at $0.18, while RSHUF trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas RSHUF's P/E ratio is -5.81. In terms of profitability, ASAPF's ROE is -0.32%, compared to RSHUF's ROE of -4.12%. Regarding short-term risk, ASAPF is less volatile compared to RSHUF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check RSHUF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, CKMTF has a market cap of 85.2M. Regarding current trading prices, ASAPF is priced at $0.18, while CKMTF trades at $12.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas CKMTF's P/E ratio is -3.32. In terms of profitability, ASAPF's ROE is -0.32%, compared to CKMTF's ROE of +2.58%. Regarding short-term risk, ASAPF is more volatile compared to CKMTF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check CKMTF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, SNZZF has a market cap of 75M. Regarding current trading prices, ASAPF is priced at $0.18, while SNZZF trades at $0.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas SNZZF's P/E ratio is -4.77. In terms of profitability, ASAPF's ROE is -0.32%, compared to SNZZF's ROE of -0.41%. Regarding short-term risk, ASAPF is more volatile compared to SNZZF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check SNZZF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, BLOZF has a market cap of 67.6M. Regarding current trading prices, ASAPF is priced at $0.18, while BLOZF trades at $0.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas BLOZF's P/E ratio is -13.96. In terms of profitability, ASAPF's ROE is -0.32%, compared to BLOZF's ROE of -2.60%. Regarding short-term risk, ASAPF is more volatile compared to BLOZF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check BLOZF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, TLTFF has a market cap of 50.1M. Regarding current trading prices, ASAPF is priced at $0.18, while TLTFF trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas TLTFF's P/E ratio is -19.50. In terms of profitability, ASAPF's ROE is -0.32%, compared to TLTFF's ROE of -3.15%. Regarding short-term risk, ASAPF is more volatile compared to TLTFF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check TLTFF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, BRNHF has a market cap of 42.1M. Regarding current trading prices, ASAPF is priced at $0.18, while BRNHF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas BRNHF's P/E ratio is -1.33. In terms of profitability, ASAPF's ROE is -0.32%, compared to BRNHF's ROE of -0.09%. Regarding short-term risk, ASAPF is more volatile compared to BRNHF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check BRNHF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, RDGL has a market cap of 40.9M. Regarding current trading prices, ASAPF is priced at $0.18, while RDGL trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas RDGL's P/E ratio is -8.99. In terms of profitability, ASAPF's ROE is -0.32%, compared to RDGL's ROE of -1.18%. Regarding short-term risk, ASAPF is more volatile compared to RDGL. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check RDGL's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, PYNKF has a market cap of 35.3M. Regarding current trading prices, ASAPF is priced at $0.18, while PYNKF trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas PYNKF's P/E ratio is 5.61. In terms of profitability, ASAPF's ROE is -0.32%, compared to PYNKF's ROE of -2.30%. Regarding short-term risk, ASAPF is more volatile compared to PYNKF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check PYNKF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, NVYTF has a market cap of 33.9M. Regarding current trading prices, ASAPF is priced at $0.18, while NVYTF trades at $0.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas NVYTF's P/E ratio is -0.86. In terms of profitability, ASAPF's ROE is -0.32%, compared to NVYTF's ROE of -0.73%. Regarding short-term risk, ASAPF is more volatile compared to NVYTF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check NVYTF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, IPDQF has a market cap of 28.5M. Regarding current trading prices, ASAPF is priced at $0.18, while IPDQF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas IPDQF's P/E ratio is -1.40. In terms of profitability, ASAPF's ROE is -0.32%, compared to IPDQF's ROE of -1.65%. Regarding short-term risk, ASAPF is more volatile compared to IPDQF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check IPDQF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, POSC has a market cap of 27.4M. Regarding current trading prices, ASAPF is priced at $0.18, while POSC trades at $1.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas POSC's P/E ratio is 0.39. In terms of profitability, ASAPF's ROE is -0.32%, compared to POSC's ROE of -3.78%. Regarding short-term risk, ASAPF is more volatile compared to POSC. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check POSC's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, MKEAF has a market cap of 25.9M. Regarding current trading prices, ASAPF is priced at $0.18, while MKEAF trades at $0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas MKEAF's P/E ratio is -4.11. In terms of profitability, ASAPF's ROE is -0.32%, compared to MKEAF's ROE of +0.50%. Regarding short-term risk, ASAPF is more volatile compared to MKEAF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check MKEAF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, KBBTF has a market cap of 24.1M. Regarding current trading prices, ASAPF is priced at $0.18, while KBBTF trades at $0.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas KBBTF's P/E ratio is -2.30. In terms of profitability, ASAPF's ROE is -0.32%, compared to KBBTF's ROE of N/A. Regarding short-term risk, ASAPF is more volatile compared to KBBTF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check KBBTF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, EMITF has a market cap of 20.1M. Regarding current trading prices, ASAPF is priced at $0.18, while EMITF trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas EMITF's P/E ratio is -8.57. In terms of profitability, ASAPF's ROE is -0.32%, compared to EMITF's ROE of -0.14%. Regarding short-term risk, ASAPF is more volatile compared to EMITF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check EMITF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, DIZTF has a market cap of 18M. Regarding current trading prices, ASAPF is priced at $0.18, while DIZTF trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas DIZTF's P/E ratio is -11.16. In terms of profitability, ASAPF's ROE is -0.32%, compared to DIZTF's ROE of -0.72%. Regarding short-term risk, ASAPF is less volatile compared to DIZTF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check DIZTF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, GTHP has a market cap of 16.7M. Regarding current trading prices, ASAPF is priced at $0.18, while GTHP trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas GTHP's P/E ratio is -4.00. In terms of profitability, ASAPF's ROE is -0.32%, compared to GTHP's ROE of +0.70%. Regarding short-term risk, ASAPF is more volatile compared to GTHP. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check GTHP's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, MDXHF has a market cap of 14.4M. Regarding current trading prices, ASAPF is priced at $0.18, while MDXHF trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas MDXHF's P/E ratio is -4.40. In terms of profitability, ASAPF's ROE is -0.32%, compared to MDXHF's ROE of +0.58%. Regarding short-term risk, ASAPF is more volatile compared to MDXHF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check MDXHF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, VPTDF has a market cap of 14.3M. Regarding current trading prices, ASAPF is priced at $0.18, while VPTDF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas VPTDF's P/E ratio is -4.14. In terms of profitability, ASAPF's ROE is -0.32%, compared to VPTDF's ROE of +1.07%. Regarding short-term risk, ASAPF is more volatile compared to VPTDF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check VPTDF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, TMDIF has a market cap of 13.9M. Regarding current trading prices, ASAPF is priced at $0.18, while TMDIF trades at $0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas TMDIF's P/E ratio is -0.65. In terms of profitability, ASAPF's ROE is -0.32%, compared to TMDIF's ROE of +8.70%. Regarding short-term risk, ASAPF is less volatile compared to TMDIF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check TMDIF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, ATBPF has a market cap of 11.4M. Regarding current trading prices, ASAPF is priced at $0.18, while ATBPF trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas ATBPF's P/E ratio is -0.86. In terms of profitability, ASAPF's ROE is -0.32%, compared to ATBPF's ROE of -0.40%. Regarding short-term risk, ASAPF is less volatile compared to ATBPF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check ATBPF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, LXXGF has a market cap of 11.3M. Regarding current trading prices, ASAPF is priced at $0.18, while LXXGF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas LXXGF's P/E ratio is -0.85. In terms of profitability, ASAPF's ROE is -0.32%, compared to LXXGF's ROE of -1.23%. Regarding short-term risk, ASAPF is more volatile compared to LXXGF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check LXXGF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, RMSL has a market cap of 10.6M. Regarding current trading prices, ASAPF is priced at $0.18, while RMSL trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas RMSL's P/E ratio is 0.66. In terms of profitability, ASAPF's ROE is -0.32%, compared to RMSL's ROE of -12.31%. Regarding short-term risk, ASAPF is more volatile compared to RMSL. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check RMSL's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, PMEDF has a market cap of 8.5M. Regarding current trading prices, ASAPF is priced at $0.18, while PMEDF trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas PMEDF's P/E ratio is -2.05. In terms of profitability, ASAPF's ROE is -0.32%, compared to PMEDF's ROE of +1.24%. Regarding short-term risk, ASAPF is more volatile compared to PMEDF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check PMEDF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, PLLWF has a market cap of 8M. Regarding current trading prices, ASAPF is priced at $0.18, while PLLWF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas PLLWF's P/E ratio is -0.66. In terms of profitability, ASAPF's ROE is -0.32%, compared to PLLWF's ROE of -0.99%. Regarding short-term risk, ASAPF is more volatile compared to PLLWF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check PLLWF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, ALRTF has a market cap of 7.5M. Regarding current trading prices, ASAPF is priced at $0.18, while ALRTF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas ALRTF's P/E ratio is -0.30. In terms of profitability, ASAPF's ROE is -0.32%, compared to ALRTF's ROE of +0.52%. Regarding short-term risk, ASAPF is more volatile compared to ALRTF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check ALRTF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, USAQ has a market cap of 6.4M. Regarding current trading prices, ASAPF is priced at $0.18, while USAQ trades at $0.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas USAQ's P/E ratio is -14.25. In terms of profitability, ASAPF's ROE is -0.32%, compared to USAQ's ROE of +0.63%. Regarding short-term risk, ASAPF is more volatile compared to USAQ. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check USAQ's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, ODYY has a market cap of 5.7M. Regarding current trading prices, ASAPF is priced at $0.18, while ODYY trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas ODYY's P/E ratio is -1.14. In terms of profitability, ASAPF's ROE is -0.32%, compared to ODYY's ROE of +0.58%. Regarding short-term risk, ASAPF is less volatile compared to ODYY. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check ODYY's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, QLIS has a market cap of 5.5M. Regarding current trading prices, ASAPF is priced at $0.18, while QLIS trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas QLIS's P/E ratio is 2.22. In terms of profitability, ASAPF's ROE is -0.32%, compared to QLIS's ROE of -0.60%. Regarding short-term risk, ASAPF is more volatile compared to QLIS. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check QLIS's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, RHNMF has a market cap of 5.4M. Regarding current trading prices, ASAPF is priced at $0.18, while RHNMF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas RHNMF's P/E ratio is -0.95. In terms of profitability, ASAPF's ROE is -0.32%, compared to RHNMF's ROE of +15.91%. Regarding short-term risk, ASAPF is less volatile compared to RHNMF. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check RHNMF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, BIEL has a market cap of 5.4M. Regarding current trading prices, ASAPF is priced at $0.18, while BIEL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas BIEL's P/E ratio is N/A. In terms of profitability, ASAPF's ROE is -0.32%, compared to BIEL's ROE of +0.05%. Regarding short-term risk, ASAPF is less volatile compared to BIEL. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check BIEL's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, ADMT has a market cap of 5.4M. Regarding current trading prices, ASAPF is priced at $0.18, while ADMT trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas ADMT's P/E ratio is -8.00. In terms of profitability, ASAPF's ROE is -0.32%, compared to ADMT's ROE of -0.01%. Regarding short-term risk, ASAPF is more volatile compared to ADMT. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check ADMT's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, NGMDF has a market cap of 4.1M. Regarding current trading prices, ASAPF is priced at $0.18, while NGMDF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas NGMDF's P/E ratio is -1.81. In terms of profitability, ASAPF's ROE is -0.32%, compared to NGMDF's ROE of +0.34%. Regarding short-term risk, ASAPF is more volatile compared to NGMDF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check NGMDF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, VANIW has a market cap of 3.4M. Regarding current trading prices, ASAPF is priced at $0.18, while VANIW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas VANIW's P/E ratio is N/A. In terms of profitability, ASAPF's ROE is -0.32%, compared to VANIW's ROE of -3.17%. Regarding short-term risk, ASAPF is less volatile compared to VANIW. This indicates potentially lower risk in terms of short-term price fluctuations for ASAPF.Check VANIW's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, CYDX has a market cap of 3.3M. Regarding current trading prices, ASAPF is priced at $0.18, while CYDX trades at $0.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas CYDX's P/E ratio is 0.82. In terms of profitability, ASAPF's ROE is -0.32%, compared to CYDX's ROE of +0.13%. Regarding short-term risk, ASAPF is more volatile compared to CYDX. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check CYDX's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, VYCO has a market cap of 3M. Regarding current trading prices, ASAPF is priced at $0.18, while VYCO trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas VYCO's P/E ratio is -9.00. In terms of profitability, ASAPF's ROE is -0.32%, compared to VYCO's ROE of +0.00%. Regarding short-term risk, ASAPF is more volatile compared to VYCO. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check VYCO's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, FZMD has a market cap of 2.6M. Regarding current trading prices, ASAPF is priced at $0.18, while FZMD trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas FZMD's P/E ratio is 1.17. In terms of profitability, ASAPF's ROE is -0.32%, compared to FZMD's ROE of +0.13%. Regarding short-term risk, ASAPF is more volatile compared to FZMD. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check FZMD's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, TBRIF has a market cap of 2.2M. Regarding current trading prices, ASAPF is priced at $0.18, while TBRIF trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas TBRIF's P/E ratio is -0.76. In terms of profitability, ASAPF's ROE is -0.32%, compared to TBRIF's ROE of +16.81%. Regarding short-term risk, ASAPF is more volatile compared to TBRIF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check TBRIF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, LLBO has a market cap of 1.7M. Regarding current trading prices, ASAPF is priced at $0.18, while LLBO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas LLBO's P/E ratio is N/A. In terms of profitability, ASAPF's ROE is -0.32%, compared to LLBO's ROE of +0.00%. Regarding short-term risk, ASAPF is more volatile compared to LLBO. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check LLBO's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, KLYG has a market cap of 1.5M. Regarding current trading prices, ASAPF is priced at $0.18, while KLYG trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas KLYG's P/E ratio is -12.01. In terms of profitability, ASAPF's ROE is -0.32%, compared to KLYG's ROE of -1.24%. Regarding short-term risk, ASAPF is more volatile compared to KLYG. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check KLYG's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, VRSEF has a market cap of 1.4M. Regarding current trading prices, ASAPF is priced at $0.18, while VRSEF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas VRSEF's P/E ratio is 0.14. In terms of profitability, ASAPF's ROE is -0.32%, compared to VRSEF's ROE of +1.00%. Regarding short-term risk, ASAPF is more volatile compared to VRSEF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check VRSEF's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, ESMC has a market cap of 1.2M. Regarding current trading prices, ASAPF is priced at $0.18, while ESMC trades at $0.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas ESMC's P/E ratio is -5.37. In terms of profitability, ASAPF's ROE is -0.32%, compared to ESMC's ROE of -125.28%. Regarding short-term risk, ASAPF is more volatile compared to ESMC. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check ESMC's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, UAHC has a market cap of 1.1M. Regarding current trading prices, ASAPF is priced at $0.18, while UAHC trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas UAHC's P/E ratio is 0.53. In terms of profitability, ASAPF's ROE is -0.32%, compared to UAHC's ROE of +0.04%. Regarding short-term risk, ASAPF is more volatile compared to UAHC. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check UAHC's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, NUMD has a market cap of 919K. Regarding current trading prices, ASAPF is priced at $0.18, while NUMD trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas NUMD's P/E ratio is 1.10. In terms of profitability, ASAPF's ROE is -0.32%, compared to NUMD's ROE of +0.23%. Regarding short-term risk, ASAPF is more volatile compared to NUMD. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check NUMD's competition here

ASAPF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ASAPF stands at 15.9M. In comparison, ELXMF has a market cap of 541.2K. Regarding current trading prices, ASAPF is priced at $0.18, while ELXMF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ASAPF currently has a P/E ratio of -20.34, whereas ELXMF's P/E ratio is -0.09. In terms of profitability, ASAPF's ROE is -0.32%, compared to ELXMF's ROE of -0.40%. Regarding short-term risk, ASAPF is more volatile compared to ELXMF. This indicates potentially higher risk in terms of short-term price fluctuations for ASAPF.Check ELXMF's competition here